Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Guardant Health Inc (GH)

Guardant Health Inc (GH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,538,280
  • Shares Outstanding, K 102,220
  • Annual Sales, $ 373,650 K
  • Annual Income, $ -405,670 K
  • 60-Month Beta 0.81
  • Price/Sales 14.53
  • Price/Cash Flow N/A
  • Price/Book 17.36
Trade GH with:

Options Overview Details

View History
  • Implied Volatility 62.58% ( -2.00%)
  • Historical Volatility 77.02%
  • IV Percentile 35%
  • IV Rank 27.86%
  • IV High 119.73% on 05/05/22
  • IV Low 40.51% on 09/08/21
  • Put/Call Vol Ratio 0.07
  • Today's Volume 505
  • Volume Avg (30-Day) 2,242
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 63,951
  • Open Int (30-Day) 55,166

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -1.43
  • Number of Estimates 7
  • High Estimate -1.04
  • Low Estimate -2.30
  • Prior Year -1.06
  • Growth Rate Est. (year over year) -34.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.49 +24.59%
on 07/18/22
57.29 -5.43%
on 08/08/22
+6.05 (+12.57%)
since 07/12/22
3-Month
31.81 +70.32%
on 05/19/22
57.29 -5.43%
on 08/08/22
+23.33 (+75.62%)
since 05/12/22
52-Week
27.65 +95.95%
on 05/12/22
133.82 -59.51%
on 09/02/21
-51.72 (-48.84%)
since 08/12/21

Most Recent Stories

More News
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved its Guardant360 ® CDx liquid biopsy test as a companion...

GH : 54.18 (+1.98%)
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit Conference in Dana Point,...

GH : 54.18 (+1.98%)
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and Blueprint Medicines Corporation (Nasdaq: BPMC) announced today they are presenting new data demonstrating that the EGFR C797X...

GH : 54.18 (+1.98%)
BPMC : 72.22 (+3.59%)
Why Guardant Health Stock Was So Healthy Today

Investors are cheered by the company's latest set of quarterly results, in spite of a deeper net loss.

GH : 54.18 (+1.98%)
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests and real-world data will be presented at the IASLC 2022 World...

GH : 54.18 (+1.98%)
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of -80% and 4.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

GH : 54.18 (+1.98%)
INBX : 24.46 (+3.95%)
Guardant Health Reports Second Quarter 2022 Financial Results

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported...

GH : 54.18 (+1.98%)
Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX),...

GH : 54.18 (+1.98%)
Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. Company...

GH : 54.18 (+1.98%)
2 Cancer-Focused Stocks That Could Soar, According to Wall Street

Let's look beyond short-term price targets analysts assign.

EXAS : 42.71 (+0.83%)
GH : 54.18 (+1.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption,...

See More

Key Turning Points

3rd Resistance Point 57.05
2nd Resistance Point 56.01
1st Resistance Point 55.09
Last Price 54.18
1st Support Level 53.13
2nd Support Level 52.09
3rd Support Level 51.17

See More

52-Week High 133.82
Fibonacci 61.8% 93.26
Fibonacci 50% 80.74
Fibonacci 38.2% 68.21
Last Price 54.18
52-Week Low 27.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar